Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 409

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 409
---
872,245 |     | $ | 536,861 |
| Former Chief Scientific Officer |     |   |  85,417 |     |   |  77,321 |
| Total                           |     | $ | 957,662 |     | $ | 614,182 |

In the year ended May 31, 2024, the Company amended its outstanding convertible note (“Note”) to its executive director to reflect additional borrowings of $ 200,000during the year and interest accrued to the date of the amended note. In the year ended May 31, 2025, the Company amended its outstanding convertible note (“Note”) to its executive director to reflect additional borrowings of $ 300,000during the year and interest accrued to the date of the amended note. The Company estimates that the nominal interest rate on the Note is less than rates that may be obtained from third parties. The Company recorded discounts of $ 35,063on the additional borrowing at an estimated effective rate of 10%, as an addition to paid-in capital. Other terms and conditions of the Note were not affected. The notes are payable in full on December 31, 2026.

F-15 DIAMIR BIOSCIENCES CORP.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS NOTE 8 — CONVERTIBLE NOTES PAYABLE(cont.)

No payments of principal or interest on the notes are required prior to maturity. The notes call for interest at 4% per annum, compounded monthly and are convertible, at the option of the holder, upon the Company’s next equity financing involving the Company’s sale of its equity securities to third party investors. Upon any conversion, all unpaid principal and accrued unpaid interest on the Notes will be exchanged for the Company’s securities at the lowest per unit price for securities sold to third parties in the next equity financing.

In addition, the Notes are due upon demand at the option of the holder when there is a liquidation event, which shall include:

| (i) | The                                                                                                                                          
 closing of the sale, lease, transfer or other disposition of all or substantially all of the assets of Company or the grant of any exclusive 
 license to any material portion of the Company’s intellectual property;                                                                      |

| (ii) | The                                                                                                                                    
 consummation of the merger or consolidation of the Company with or into another entity (except a merger or consolidation in which the  
 holders of capital stock of the Company immediately prior to such merger or consolidation continue to hold, directly or indirectly, at